MDMA therapy for PTSD faces a delayed US path after FDA rejection, with MAPS-linked developers seeking new evidence, safety safeguards, and a possible 2026 return

MDMA-assisted therapy for PTSD remains delayed in the United States after an FDA rejection pushed likely timelines beyond the first expected approval window. Developers tied to the MAPS ecosystem are repositioning around additional clinical evidence, stricter safety oversight, and revised regulatory strategy that could support a renewed filing in 2026. PTSD treatment remains the central medical target, but the setback also reflects broader concerns about therapist conduct, trial integrity, abuse potential, and whether psychotherapy-dependent drug protocols can be standardized for approval. Regulatory caution now shapes investor expectations, commercial planning, and the wider psychedelic medicine sector. A 2026 pathway depends on stronger data, cleaner study design, and clearer risk management. MDMA's future in psychiatry therefore hinges not only on efficacy signals, but also on credibility, training standards, and the FDA's confidence that benefits outweigh harms in real-world care.